Oruka Therapeutics (ORKA) had its price target raised by Barclays PLC from $48.00 to $50.00. They now have an "overweight" rating on the stock.
Oruka Therapeutics (ORKA) had its "buy" rating reaffirmed by BTIG Research. They now have a $73.00 price target on the stock.
Oruka Therapeutics (ORKA) had its price target raised by Stifel Nicolaus from $47.00 to $72.00. They now have a "buy" rating on the stock.
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update